INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
BRISBANE, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM 434, an Activin
View HTML
Toggle Summary Atara Biotherapeutics Announces Pricing of Its Initial Public Offering
BRISBANE, Calif., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock
View HTML
Toggle Summary Atara Biotherapeutics Announces Immunotherapy Alliance with Memorial Sloan Kettering Cancer Center
– T-cell Technology Harnesses Immune System to Fight Cancer and Infectious Disease –
View HTML
Toggle Summary Atara Biotherapeutics Strengthens Board; Senior Management Team
– Matthew K. Fust joins Board of Directors – – Mitchall G. Clark named Chief Regulatory and Quality Assurance Officer –
View HTML
Toggle Summary Atara Biotherapeutics Announces Second Closing of $52 Million Series B Financing
– Management to Present at the 32nd Annual J.P. Morgan Healthcare Conference –
View HTML
Toggle Summary Atara Biotherapeutics Secures $38.5 Million Series B Financing
– Accelerates Two Development-Stage Compounds – – Appoints Joel Marcus as New Board Member –
View HTML
Toggle Summary Research Findings Presented at 2013 ASCO Annual Meeting
Research Findings Presented at 2013 ASCO Annual Meeting A team of oncology researchers including Dr. Christopher Haqq, Atara Biotherapeutics’ Chief Medical Officer, presented a poster at the June 2013 annual meeting of the American Society of Clinical Oncology in Chicago.
View HTML
Toggle Summary Amgen and KPCB Partner to Create Atara Biotherapeutics AMGEN AND KLEINER PERKINS CAUFIELD & BYERS PARTNER TO CREATE NEW SPIN-OUT BIOTECH COMPANY
Amgen to License Pipeline Assets to Newly Formed Company
View HTML